LONDON (ShareCast) - Specialty pharmaceutical firm Sinclair Pharma (LSE: SPH.L - news) has announced the results of a new study into its eczema treatment for children. The drug developer said the results of a new US paediatric study into Atopiclair, were positive, showing a significant improvement of mild to moderate atopic eczema for infants and children.
